Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark E Jones

Showing results (21-30 of 65) with videos related to

Pageof 7
Sort By:
Antimicrobial Agents and Chemotherapy|August 17, 2002
Prevalence of oxacillin resistance in Staphylococcus aureus among inpatients and outpatients in the United States during 2000Mark E Jones, David C Mayfield, Clyde Thornsberry, et al.
International Journal of Antimicrobial Agents|October 3, 2003
Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapyMark E Jones, James A Karlowsky, Deborah C Draghi, et al.
The Annals of Pharmacotherapy|December 21, 2007
Differences between ceftriaxone and cefotaxime: microbiological inconsistenciesJohn G Gums, D Wesston Boatwright, Mark Camblin, et al.
International Journal of Antimicrobial Agents|May 29, 2004
Antibiotic susceptibility of bacteria most commonly isolated from bone related infections: the role of cephalosporins in antimicrobial therapyMark E Jones, James A Karlowsky, Deborah C Draghi, et al.
International Journal of Antimicrobial Agents|February 19, 2002
Apparent plateau in beta-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the LIBRA Surveillance initiativeMark E Jones, James A Karlowsky, Renée Blosser-Middleton, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 22, 2002
The stability of grlA, grlB, gyrA, gyrB and norA mutations and MIC values of five fluoroquinolones in three different clonal populations of methicillin-resistant Staphylococcus aureusFranz-Josef Schmitz, Karl Köhrer, Sybille Scheuring, et al.
Antimicrobial Agents and Chemotherapy|September 25, 2003
In vitro susceptibilities of gram-negative bacteria isolated from hospitalized patients in four European countries, Canada, and the United States in 2000-2001 to expanded-spectrum cephalosporins and comparator antimicrobials: implications for therapyRichard P Wenzel, Daniel F Sahm, Clyde Thornsberry, et al.
Diagnostic Microbiology and Infectious Disease|February 1, 2002
Activity of cefditoren against beta-lactamase-positive and -negative Haemophilus influenzae and Moraxella catarrhalisJames A Karlowsky, Ian A Critchley, Deborah C Draghi, et al.
International Journal of Antimicrobial Agents|September 26, 2002
Antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in two successive respiratory seasons in the USJames A Karlowsky, Deborah C Draghi, Clyde Thornsberry, et al.
Future Microbiology|January 11, 2020
Ceftobiprole versus daptomycin in <i>Staphylococcus aureus</i> bacteremia: a novel protocol for a double-blind, Phase III trialKamal Hamed, Marc Engelhardt, Mark E Jones, et al.
Pageof 7

Showing results (21-30 of 65) with videos related to

Sort By:
Pageof 7
Antimicrobial Agents and Chemotherapy|August 17, 2002
Prevalence of oxacillin resistance in Staphylococcus aureus among inpatients and outpatients in the United States during 2000Mark E Jones, David C Mayfield, Clyde Thornsberry, et al.
International Journal of Antimicrobial Agents|October 3, 2003
Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapyMark E Jones, James A Karlowsky, Deborah C Draghi, et al.
The Annals of Pharmacotherapy|December 21, 2007
Differences between ceftriaxone and cefotaxime: microbiological inconsistenciesJohn G Gums, D Wesston Boatwright, Mark Camblin, et al.
International Journal of Antimicrobial Agents|May 29, 2004
Antibiotic susceptibility of bacteria most commonly isolated from bone related infections: the role of cephalosporins in antimicrobial therapyMark E Jones, James A Karlowsky, Deborah C Draghi, et al.
International Journal of Antimicrobial Agents|February 19, 2002
Apparent plateau in beta-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the LIBRA Surveillance initiativeMark E Jones, James A Karlowsky, Renée Blosser-Middleton, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 22, 2002
The stability of grlA, grlB, gyrA, gyrB and norA mutations and MIC values of five fluoroquinolones in three different clonal populations of methicillin-resistant Staphylococcus aureusFranz-Josef Schmitz, Karl Köhrer, Sybille Scheuring, et al.
Antimicrobial Agents and Chemotherapy|September 25, 2003
In vitro susceptibilities of gram-negative bacteria isolated from hospitalized patients in four European countries, Canada, and the United States in 2000-2001 to expanded-spectrum cephalosporins and comparator antimicrobials: implications for therapyRichard P Wenzel, Daniel F Sahm, Clyde Thornsberry, et al.
Diagnostic Microbiology and Infectious Disease|February 1, 2002
Activity of cefditoren against beta-lactamase-positive and -negative Haemophilus influenzae and Moraxella catarrhalisJames A Karlowsky, Ian A Critchley, Deborah C Draghi, et al.
International Journal of Antimicrobial Agents|September 26, 2002
Antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in two successive respiratory seasons in the USJames A Karlowsky, Deborah C Draghi, Clyde Thornsberry, et al.
Future Microbiology|January 11, 2020
Ceftobiprole versus daptomycin in <i>Staphylococcus aureus</i> bacteremia: a novel protocol for a double-blind, Phase III trialKamal Hamed, Marc Engelhardt, Mark E Jones, et al.
Pageof 7